|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM033060673 |
| 003 |
DE-627 |
| 005 |
20250126162726.0 |
| 007 |
tu |
| 008 |
231221s1987 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed25n0111.xml
|
| 035 |
|
|
|a (DE-627)NLM033060673
|
| 035 |
|
|
|a (NLM)3324778
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Sacco, A G
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Zona pellucida
|b current status as a candidate antigen for contraceptive vaccine development
|
| 264 |
|
1 |
|c 1987
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 18.03.1988
|
| 500 |
|
|
|a Date Revised 04.04.2017
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a The porcine zona pellucida represents a unique immunocontraceptive target antigen. Initial active immunization studies using crude or partially purified zona components as immunogens resulted in adverse, nonreversible effects on ovarian folliculogenesis, but more recent findings in nonhuman primates indicate that such effects are not as severe and are reversible. Consequently, current efforts are directed toward identifying a zona immunogen that elicits contraceptive antibodies that produce no adverse effects on the ovary. Other studies are in progress to determine optimal injection/immunization format, proper immunogen dosage, and appropriate adjuvant for use in the zona-antizona immunocontraceptive system. Recent data have been very encouraging and emphasize the contraceptive efficacy of this approach to reproduction control
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Antibodies
|
| 650 |
|
4 |
|a Antigen-antibody Reactions
|
| 650 |
|
4 |
|a Biology
|
| 650 |
|
4 |
|a Contraception
|
| 650 |
|
4 |
|a Contraception Research
|
| 650 |
|
4 |
|a Contraception, Immunological
|
| 650 |
|
4 |
|a Examinations And Diagnoses
|
| 650 |
|
4 |
|a Family Planning
|
| 650 |
|
4 |
|a Female Contraception
|
| 650 |
|
4 |
|a Genitalia
|
| 650 |
|
4 |
|a Genitalia, Female
|
| 650 |
|
4 |
|a Immunity
|
| 650 |
|
4 |
|a Immunity, Active
|
| 650 |
|
4 |
|a Immunologic Factors
|
| 650 |
|
4 |
|a Laboratory Examinations And Diagnoses
|
| 650 |
|
4 |
|a Ovarian Effects
|
| 650 |
|
4 |
|a Ovary
|
| 650 |
|
4 |
|a Physiology
|
| 650 |
|
4 |
|a Urogenital System
|
| 650 |
|
4 |
|a Vaccines
|
| 650 |
|
7 |
|a Vaccines
|2 NLM
|
| 773 |
0 |
8 |
|i Enthalten in
|t American journal of reproductive immunology and microbiology : AJRIM
|d 1985
|g 15(1987), 4 vom: 15. Dez., Seite 122-30
|w (DE-627)NLM023911689
|x 8755-8920
|7 nnns
|
| 773 |
1 |
8 |
|g volume:15
|g year:1987
|g number:4
|g day:15
|g month:12
|g pages:122-30
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_21
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_92
|
| 912 |
|
|
|a GBV_ILN_110
|
| 912 |
|
|
|a GBV_ILN_131
|
| 912 |
|
|
|a GBV_ILN_203
|
| 912 |
|
|
|a GBV_ILN_227
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_606
|
| 912 |
|
|
|a GBV_ILN_657
|
| 912 |
|
|
|a GBV_ILN_791
|
| 912 |
|
|
|a GBV_ILN_1016
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 15
|j 1987
|e 4
|b 15
|c 12
|h 122-30
|